Navigation Links
SIRO ClinPharm and Advanced Clinical Trial Solutions Ink Strategic Alliance
Date:4/17/2009

Alliance provides global oncology clinical development solutions in North America, Europe and India.

PRINCETON, N.J., April 17 /PRNewswire/ -- SIRO ClinPharm (SIRO), a leading multinational Contract Research Organization (CRO), today announced the signing of a strategic alliance with Advanced Clinical Trial Solutions LLC (ACT Solutions), Flemington, NJ, USA, a service provider in oncology drug development with a business concentration in North America. This alliance will enable SIRO to expand its oncology clinical development and patient recruitment expertise to North America. ACT Solutions and its clients will benefit by gaining access to SIRO's clinical study management, patient recruitment, data management, biostatistics and medical writing capabilities in India and European countries.

"We are delighted to add ACT Solution's North American expertise in our service offering to our customers, said Dr Chetan Tamhankar, COO of SIRO ClinPharm group. "This alliance is the first step for SIRO in creating delivery capabilities in North America."

"We are excited about aligning our strengths in oncology with SIRO's international delivery capabilities," said Patricia Devitt Risse, Pharm. D, President of ACT Solutions LLC. "This step addresses the changing dynamics of the clinical research sector. We remain committed to providing a level of expertise and service that built our reputation and loyal client base to this point and this alliance expands our ability to deliver capabilities in Europe and India," she explained.

According to Patricia Terek, President of SIRO ClinPharm, USA, "This step will help meet the growing needs of our oncology customers to have access to operational capabilities in North America. We are excited to offer the clinical development expertise of ACT Solutions in North America to our customers globally."

About SIRO

SIRO is a leading multinational contract research organization. With a presence in over 15 countries across North America, Europe and Asia, SIRO offers global bio-technology and pharmaceutical companies end to end clinical trial services. Established in year 1996, SIRO has emerged as a leading name for high speed and optimal cost of conducting clinical research. More information about the SIRO group is available at www.siroclinpharm.com

About Advanced Clinical Trial Solutions LLC

Advanced Clinical Trial Solutions LLC (ACT Solutions) is a privately held company that is devoted to operational excellence in global oncology drug development. ACT Solutions is staffed solely with experienced oncology personnel that has enabled it to grow its business annually and to establish strategic partnerships to expand the scope of the ACT Solutions service offerings. More information about ACT Solutions is available at www.actsolutions.org


'/>"/>
SOURCE SIRO ClinPharm
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. NexBio Completes Clinical Advisory Board for the Advanced Development of DAS181 (Fludase(R)*), a First-In-Class Medicine for Influenza
2. PROVENGE Significantly Prolongs Survival in Men With Advanced Prostate Cancer in Pivotal Phase 3 IMPACT Study
3. Advanced Life Sciences Announces Filing of Shelf Registration Statement
4. The Journal of Cardiac Failure Publishes Results From Celladon Corporations First-in-Human Phase 1/2 Clinical Trial in Advanced Heart Failure
5. METTLER TOLEDO and AAPS: Utilization of Process Modeling and Advanced Process Control in QbD based Drug Development and Manufacturing
6. Roche to Introduce New LightCycler(R) MRSA Advanced Test in the EU
7. iCardiac Applies Advanced Cardiac Safety Biomarkers in Clinical Study for Top Pharmaceutical Company
8. New White Paper Examines Advanced Mycoplasma Tests - How Real-Time PCR Analysis Helps Save Time and Money for Biopharmaceutical Manufacturers
9. Leading Middle East Cancer Hospital Acquires Advanced Radiotherapy Capability from Varian Medical Systems
10. Sigma-Aldrich Streamlines Access to Advanced Stem Cell Research Portfolio and Opens Stem Cell Biology Community Through New Web Portal
11. ClearTrial Launches Version 2.7 of its Clinical Trial Operations Planning Software Featuring Advanced Portfolio Planning Capability
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... New York, NY (PRWEB) , ... October 12, ... ... York Academy of Sciences today announced the three Winners and six Finalists of ... Awards are given annually by the Blavatnik Family Foundation and administered by the ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... the first-ever genomics analysis platform specifically designed for life science researchers to ... of pioneering researcher Rosalind Franklin, who made a major contribution to the ...
(Date:10/11/2017)... ... 11, 2017 , ... Proscia Inc ., a data ... titled, “Pathology is going digital. Is your lab ready?” with Dr. Nicolas Cacciabeve, ... and how Proscia improves lab economics and realizes an increase in diagnostic confidence.* ...
(Date:10/11/2017)... ... October 11, 2017 , ... Singh Biotechnology today announced ... to SBT-100, its novel anti-STAT3 (Signal Transducer and Activator of Transcription 3) B ... to cross the cell membrane and bind intracellular STAT3 and inhibit its function. ...
Breaking Biology Technology:
(Date:5/16/2017)... 16, 2017   Bridge Patient Portal , ... MD EMR Systems , an electronic medical ... GE, have established a partnership to build an ... the GE Centricity™ products, including Centricity Practice Solution ... These new integrations will allow healthcare delivery ...
(Date:4/18/2017)...  Socionext Inc., a global expert in SoC-based imaging and computing ... M820, which features the company,s hybrid codec technology. A demonstration utilizing ... Inc., will be showcased during the upcoming Medtec Japan at Tokyo ... Las Vegas Convention Center April 24-27. ... Click here for an image ...
(Date:4/11/2017)... 11, 2017 Crossmatch®, a globally-recognized leader ... today announced that it has been awarded a ... Activity (IARPA) to develop next-generation Presentation Attack Detection ... "Innovation has been a driving force within Crossmatch ... allow us to innovate and develop new technologies ...
Breaking Biology News(10 mins):